Citi initiated coverage of Alnylam with a Buy rating and $380 price target. The expanded launch of Amvuttra for ATTR-CM has \"no doubt been impressive,\" says the analyst, who views 28% year-to-date pullback as \"an attractive long-term entry point.\" Pressure has been led by competitor concerns, but the firm sees \"more tailwinds than headwinds for Amvuttra,\" the analyst added.
